Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Forecasts Tripling In Reported Op Profit Despite Virus Uncertainties

Lower Shire-Related Costs

Executive Summary

While it has seen no coronavirus-related business impact so far and uncertainties remain, Takeda expects lower costs related to the Shire acquisition to propel its profits this fiscal year.

You may also be interested in...



EU Approves Takeda’s Injectable Entyvio for IBD

Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.

Takeda Sheds More Non-Core Assets, Employees In $670m Orifarm Deal

Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.

Takeda Kicks Off Effort On Globulin, Other COVID-19 Therapies

Japan's largest pharma firm has joined the global fray to develop potential therapies for the spreading coronavirus outbreak, focusing initially on its plasma products expertise. But this approach has had some challenges in China.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel